What you carry at this position in your DNA and what research says about it.
Heart and Cancer Risk: 5/10 evidence, 9 publications.
You're viewing every possible genotype for this variant.
None of these is your result. Use the genotype toggle to compare them, then sign up and upload your DNA to see which one is yours.
Sample genotype (not yours): A/A
Typical Heart and Cancer Risk
Standard genetic baseline carries typical risks for cardiovascular conditions and cancer. Standard clinical guidelines apply for routine health screenings.
What this genotype means: Typical baseline risk for heart disease; Standard response to platinum-based chemotherapy.
Sample genotype (not yours): A/G
Lower Heart and Cancer Risk
One copy of the protective G allele lowers the risk of heart disease and several cancers. A minor trade-off includes a potentially reduced response to certain chemotherapy drugs.
What this genotype means: Reduced risk of coronary artery disease; Lower susceptibility to breast and thyroid cancers; Potentially reduced sensitivity to platinum chemotherapy.
Sample genotype (not yours): G/G
Lowest Heart and Cancer Risk
Two copies of the protective G allele offer the strongest defense against heart disease and cancer. This profile may also reduce the effectiveness of platinum-based chemotherapy.
What this genotype means: Strongest genetic protection against coronary artery disease; Lowest risk of pulmonary arterial hypertension; Reduced response to platinum-based chemotherapy.
Gene function and biological role
Gene Function: The MALAT1 gene encodes a highly conserved long non-coding RNA that plays a critical role in regulating gene expression, splicing, and cell cycle progression. Unlike typical genes, it does not produce a protein but instead functions as a structural and regulatory RNA molecule in the cell nucleus. It is widely expressed throughout the body and is heavily involved in cellular survival, blood vessel growth, and inflammatory responses. Because it influences how cells grow and migrate, its activity levels are closely linked to cardiovascular health and tumor development.
Variant Impact: The rs619586 variant is a single nucleotide change located within the non-coding sequence of the MALAT1 gene. This specific genetic change alters the expression levels of the MALAT1 transcript, which in turn influences downstream cellular pathways. The minor G allele is associated with decreased expression of MALAT1, which helps limit abnormal cell proliferation and blood vessel remodeling [1]. Consequently, this variant has been widely studied for its protective effects against several vascular and oncological conditions [2].
Key Insight: The rare G allele of this variant acts as a natural shield that lowers the risk of multiple major health conditions, including heart disease and several types of cancer, by naturally reducing the expression of a gene associated with tumor growth and blood vessel thickening.
Location: MALAT1. Chromosome 11 · 11q13.1 · 65.5 Mb
Estimated prevalence by population
Global 93.1%; European 93.0%; African 97.7%; East Asian 83.0%; South Asian 74.3%; Americas 89.6%; Ashkenazi 97.3%; Finnish 92.6%; Middle Eastern 99.3%; Amish 98.7%.
Estimated AA genotype frequency.
Global 6.7%; European 6.9%; African 2.3%; East Asian 16.2%; South Asian 23.8%; Americas 10.1%; Ashkenazi 2.7%; Finnish 7.2%; Middle Eastern 0.7%; Amish 1.3%.
Estimated AG genotype frequency.
Global 0.2%; European 0.1%; African < 0.1%; East Asian 0.8%; South Asian 1.9%; Americas 0.3%; Ashkenazi < 0.1%; Finnish 0.1%; Middle Eastern < 0.1%; Amish < 0.1%.
Estimated GG genotype frequency.
Showing effects for A/A genotype
Cardiovascular & Metabolic
Heart Disease
Heart Disease. Evidence: 3/10. Source: PMID 30833365. Typical Risk.
Hypertension
Pulmonary Hypertension. Evidence: 3/10. Source: PMID 27362960. Typical Risk.
Cancer & Oncology
General Cancer Risk
Cancer Susceptibility. Evidence: 5/10. Source: PMID 29146194. Typical Risk.
Pharmacogenomics
Chemotherapy Response
Chemotherapy Response. Evidence: 5/10. Source: PMID 26729200. Typical Response.
Showing effects for A/G genotype
Heart Disease. Evidence: 3/10. Source: PMID 30833365. Lower Risk.
Pulmonary Hypertension. Evidence: 3/10. Source: PMID 27362960. Lower Risk.
Cancer Susceptibility. Evidence: 5/10. Source: PMID 29146194. Lower Risk.
Chemotherapy Response. Evidence: 5/10. Source: PMID 26729200. Poorer Response.
Showing effects for G/G genotype
What this genotype means for the people who carry it
Sample genotype: AA (Homozygous)
Inheriting two copies of the common A allele represents the baseline genetic profile for the majority of the global population. This genotype is associated with standard, average susceptibility to coronary artery disease and various cancers [1] [2]. Because there is no protective G allele present to naturally downregulate MALAT1 expression, cellular proliferation and vascular remodeling proceed at typical rates [3]. For individuals requiring treatment for certain lung cancers, this genotype is associated with a standard, favorable response to platinum-based chemotherapy drugs [4]. Maintaining routine cardiovascular screenings and standard cancer prevention strategies remains the most effective approach to long-term health.
Typical baseline risk for heart disease; Standard response to platinum-based chemotherapy.
Sample genotype: AG (Heterozygous)
Carrying a single copy of the protective G allele is associated with a significantly reduced risk of developing coronary artery disease [1]. This genetic variant helps lower the expression of the MALAT1 transcript, which limits abnormal cell growth and protects blood vessels from excessive thickening [2]. Research also indicates a lower susceptibility to several cancers, including breast, thyroid, and lung cancers [3]. However, this same reduction in gene expression may lead to a poorer therapeutic response if platinum-based chemotherapy is ever required [4]. Overall, the cardiovascular and oncological protective benefits of this genotype provide a highly favorable health outlook.
Reduced risk of coronary artery disease; Lower susceptibility to breast and thyroid cancers; Potentially reduced sensitivity to platinum chemotherapy.
Sample genotype: GG (Homozygous)
Inheriting two copies of the protective G allele provides the maximum genetic shield against coronary artery disease and pulmonary hypertension [1] [2]. By significantly reducing the activity of the MALAT1 gene, this genotype prevents the cellular overgrowth and vessel wall thickening that contribute to cardiovascular strain [2]. It also correlates with the lowest susceptibility to various solid tumors, including breast and thyroid cancers [3]. The primary clinical caveat is a reduced sensitivity to platinum-based chemotherapy agents, which rely on specific cellular pathways that are less active with this genotype [4]. Despite this conditional drug response, the overall health profile remains highly protective against major chronic diseases.
Strongest genetic protection against coronary artery disease; Lowest risk of pulmonary arterial hypertension; Reduced response to platinum-based chemotherapy.
Variants with shared genetic architecture
rs3200401 · MALAT1 Gene · Chr 11 · Periodontitis and Metabolic Risk
rs11615 · ERCC1 Gene · Chr 19 · DNA Repair and Cancer Risk
rs1799782 · XRCC1 Gene · Chr 19 · Cancer Risk
Content updated August 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com